Study On Proteomics Of The Serum Biomarker From Children With HSP

Objective: The henoch-schonlein purpura is one kind of hypersensitivity vasculitis of capillary vessel and renal vessels, its clinical manifestation assumes the multiplicity, take the skin, the digestive tract, the joint and the kidney harm as the main performance. The typical case of illness easy to diagnose, in which skin harm is the essential condition of HSP. When the skin harm appears late and abdominal pain as first symptom, the early diagnosis is quite difficult because HSP have not the skin purpura. Because the clinical manifestation and the assistance inspection lacks the specificity, clinician to the abdomen allergic purpura understanding insufficiency, HSP often first impressions ares most lasting induces illness the gastro-intestinal tract disease category, extremely easy to misdiagnose, leaks examines. The HSP's long-term prognosis mainly is decided the degree which implicates in the kidney, harms the degree aggravation along with the kidney, the recrudescence number of times increases, the course of an illness lengthens, the prognosis is bad. There is about 30% -60% of the performance of kidney damage with HSP, the incidence of HSPN as people recognize the depth is gradually increased. The kidney harm picks out rate related to the inspection method,We could not deny his/her Kidney harm in the routine urine test normal .If the early time only take the clinical urine change as the diagnosis basis, HSPN picks out rate is 20%-60%.Judges the kidney harm or not and exhausts oneself the degree direct target is the kidney biopsy, overseas take the kidney biopsy as the diagnosis basis, HSPN picks out rate may reach as high as above 90%.But the kidney biopsy for has creates the inspection, its duplication is bad, does not favor the clinical promotion, very few uses the early diagnosis in HSPN. The technology of"Surface enhanced laser desorption /ionization-time of flight-mass spectrometry"(SELDI-TOF- MS) was adopted with protein chip to test the differential expressions among HSP, HSPN and the serum protein spectrum from normal children. Serum protein maker was sieved for both the early diagnosis and grouping of HSP and HSPN. Provides the clinical basis for disease early diagnosis and the treatment starts the more appropriate treatment plan as soon as possible, prompt and effective control condition, improvement trouble prognosis. Methods: SELDI-TOF-MS was applied to test the serum protein combined with the protein chip. 55 cases of HSP, 20 cases of HSPN, 30 finger prints of serum protein from the control group were collected. Biomarker Wizard and the software of Biomarker Patterns System 5.0 were applied to analyze the data and a diagnostic model is established. Results: Within the range of mass electron ration (m/z) of 2000-20000, when a contrast was made between the HSP group and the control group, 59 protein peaks were statistically significant (p<0.01), 39 peaks of which were of high expression and 20 with low expression. The most significant protein was that with the m/z of 2102.73 2416.80 2882.40 3967.83 4224.14, which could be recognized as serum biomarker for HSP. 103 protein peaks were found statistically significant (p<0.01) between the HSPN group and HSP without the kidney harm group, 44 of which were of high expression and 59 with low expression. The most significant protein was that with the m/z of 2367.87 3283.93 4656.80 5926.77 8927.69 9279.21, which could be recognized as serum biomarker for HSPN. Those proteins with m/z of 2416.80 aren't found by searching the protein library and they may be new proteins. By integrating respective serum biomarker from the two types of protein into the diagnostic model of artificial neural network, the HSP group and the control group could be divided accurately with the sensitivity of 90.9%, specificity of 77.7%; and the integration's sensitivity to the diagnostic model of the HSPN group and HSP without the kidney harm was 100%, specificity was 95.2%. Conclusions: We conclude that 1) There is a significant difference between the levels of serum protein from the HSP group and normal children.; 2)There is a significant difference between the levels of serum protein from the group of the HSPN group and HSP without the kidney harm; 3)The diagnostic model of protein combination, with m/z of 2102.73 2416.80 2882.40 3967.83 4224.14 can completely and accurately distinguish the HSP group and the control group of normal children, therefore this kind of protein might be the serum biomarker for HSP.M/z of 2416.80 may be new proteins; 4) The diagnostic model of protein combination, with m/z of 2367.87 3283.93 4656.80 5926.77 8927.69 9279.21 can accurately HSPN group and HSP without the kidney harm group. The discrepant protein supplied is helpful to learn about the molecule mechanism of the different features between HSPN and HSP without the kidney harm, thus possibility for targeted therapy is provided and the above-mentioned protein might be the serum biomarker for chronic HSP. 5) SELI-TOF-MS technology is an effective tool to seek tool to seek disease related proteins.